Abstract This retrospective study evaluates the respiratory impact of exclusive cannabis use via traditional pipes in asthmatic patients (n=7) compared to a non-smoking control group (n=54) to assess the clinical and functional consequences of this practice. The results demonstrate increased morbidity among cannabis users, marked by a high prevalence of dry cough (71%) and dyspnea (57%), as well as significant lung function impairment with a mean FEV1 of 65% and a Tiffeneau index of 0.60. The study concludes that inhaled cannabis use seriously complicates asthma control, requiring higher therapeutic steps (GINA Step 4) and promoting persistent bronchial inflammation and accelerated functional decline compared to non-smoking patients.
M et al. (2026) studied this question.